120 related articles for article (PubMed ID: 1847127)
21. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
Lee J; Park JO; Kim WS; Park SH; Park KW; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC; Joh J; Kim K; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Park K
Cancer Chemother Pharmacol; 2004 Nov; 54(5):385-90. PubMed ID: 15248028
[TBL] [Abstract][Full Text] [Related]
22. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Gaspar LE; Winter K; Kocha WI; Coia LR; Herskovic A; Graham M
Cancer; 2000 Mar; 88(5):988-95. PubMed ID: 10699886
[TBL] [Abstract][Full Text] [Related]
23. Radiotherapy with high dose rate brachytherapy boost and concomitant chemotherapy for Stages IIB and III esophageal carcinoma: results of a pilot study.
Calais G; Dorval E; Louisot P; Bourlier P; Klein V; Chapet S; Reynaud-Bougnoux A; Huten N; De Calan L; Aget H; Le Floch O
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):769-75. PubMed ID: 9240645
[TBL] [Abstract][Full Text] [Related]
24. Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-flourouracil for unresectable advanced hepatocellular carcinoma.
Lin CP; Yu HC; Cheng JS; Lai KH; Lo GH; Hsu PI; Lin CK; Chen HH; Lo CC; Liang HL; Tseng HH
J Chin Med Assoc; 2004 Dec; 67(12):602-10. PubMed ID: 15779483
[TBL] [Abstract][Full Text] [Related]
25. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.
Budach V; Stuschke M; Budach W; Baumann M; Geismar D; Grabenbauer G; Lammert I; Jahnke K; Stueben G; Herrmann T; Bamberg M; Wust P; Hinkelbein W; Wernecke KD
J Clin Oncol; 2005 Feb; 23(6):1125-35. PubMed ID: 15718308
[TBL] [Abstract][Full Text] [Related]
26. Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study.
Bensadoun RJ; Etienne MC; Dassonville O; Chauvel P; Pivot X; Marcy PY; Prevost B; Coche-Dequeant B; Bourdin S; Vallicioni J; Poissonnet G; Courdi A; Teissier E; Lagrange JL; Thyss A; Santini J; Demard F; Schneider M; Milano G
Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):237-45. PubMed ID: 9788400
[TBL] [Abstract][Full Text] [Related]
27. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
Leung TW; Tang AM; Zee B; Yu SC; Lai PB; Lau WY; Johnson PJ
Cancer; 2002 Jan; 94(2):421-7. PubMed ID: 11905412
[TBL] [Abstract][Full Text] [Related]
28. Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study.
Al-Sukhun S; Zalupski MM; Ben-Josef E; Vaitkevicius VK; Philip PA; Soulen R; Weaver D; Adsay V; Heilbrun LK; Levin K; Forman JD; Shields AF
Am J Clin Oncol; 2003 Dec; 26(6):543-9. PubMed ID: 14663369
[TBL] [Abstract][Full Text] [Related]
29. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M;
J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967
[TBL] [Abstract][Full Text] [Related]
30. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02.
Murray KJ; Nelson DF; Scott C; Fischbach AJ; Porter A; Farnan N; Curran WJ
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):453-9. PubMed ID: 7852106
[TBL] [Abstract][Full Text] [Related]
31. Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem.
Lygidakis NJ; Kosmidis P; Ziras N; Parissis J; Kyparidou E
J Interferon Cytokine Res; 1995 May; 15(5):467-72. PubMed ID: 7544232
[TBL] [Abstract][Full Text] [Related]
32. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
Nelson DF; Curran WJ; Scott C; Nelson JS; Weinstein AS; Ahmad K; Constine LS; Murray K; Powlis WD; Mohiuddin M
Int J Radiat Oncol Biol Phys; 1993 Jan; 25(2):193-207. PubMed ID: 8380567
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
Yamasaki T; Kimura T; Kurokawa F; Aoyama K; Ishikawa T; Tajima K; Yokoyama Y; Takami T; Omori K; Kawaguchi K; Tsuchiya M; Terai S; Sakaida I; Okita K
J Gastroenterol; 2005 Jan; 40(1):70-8. PubMed ID: 15692792
[TBL] [Abstract][Full Text] [Related]
34. Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study.
Tanaka K; Yabushita Y; Nakagawa K; Kumamoto T; Matsuo K; Taguri M; Endo I
Eur J Surg Oncol; 2013 Dec; 39(12):1364-70. PubMed ID: 24183169
[TBL] [Abstract][Full Text] [Related]
35. Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92-10.
Grigsby PW; Lu JD; Mutch DG; Kim RY; Eifel PJ
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):817-22. PubMed ID: 9652843
[TBL] [Abstract][Full Text] [Related]
36. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04.
Komaki R; Scott C; Ettinger D; Lee JS; Fossella FV; Curran W; Evans RF; Rubin P; Byhardt RW
Int J Radiat Oncol Biol Phys; 1997 Apr; 38(1):149-55. PubMed ID: 9212017
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
[TBL] [Abstract][Full Text] [Related]
38. Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer.
Wong WW; Mick R; Haraf DJ; Weichselbaum RR; Vokes EE
Int J Radiat Oncol Biol Phys; 1994 Apr; 29(1):153-62. PubMed ID: 8175423
[TBL] [Abstract][Full Text] [Related]
39. Strong correlation between imaging response and survival among patients with primary central nervous system lymphoma: a secondary analysis of RTOG studies 83-15 and 88-06.
Corn BW; Dolinskas C; Scott C; Donahue B; Schultz C; Nelson DF; Fisher B
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):299-303. PubMed ID: 10802352
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. A randomized phase II study of the cancer and leukemia group B.
Richards F; Perry DJ; Goutsou M; Modeas C; Muchmore E; Rege V; Chahinian AP; Hirsh V; Poiesz B; Green MR
Cancer; 1991 Jun; 67(12):2974-9. PubMed ID: 1646066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
